Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRÎ±ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRÎ±ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Related Posts

Home-builder ETFs down in 2025 after brutal February as these worries weigh

Home-builder ETFs down in 2025 after brutal February as...

‘She’s not working outside the home’: My mother, 63, inherited $100,000. Is she too old to invest in the stock market?

‘She’s not working outside the home’: My mother, 63, in...

Alliance Entertainment CEO Jeffrey Walker buys $2.69 billion in stock

Alliance Entertainment CEO Jeffrey Walker buys $2.69 bi...

Rocket Lab makes ‘bold’ satellite move, but shares slide on weak outlook

Rocket Lab makes ‘bold’ satellite move, but shares slid...

Canada watchdog probing X's use of personal data in AI models' training

Canada watchdog probing X's use of personal data in AI ...

Social Security Administration announces ‘massive’ reorganization, ‘significant’ job cuts

Social Security Administration announces ‘massive’ reor...